Bandingkan kaedah

	Indeks Kanser Prostat UCLA: Penilaian Fungsian Kualiti Hidup Khusus Prostat	EORTC QLQ-BR23: Kualiti Hidup dalam Kanser Payudara
Bidang	Onkologi	Onkologi
Keluarga	Process / pipeline	Process / pipeline
Tahun asal	1998	1996
Pengasas	Litwin, M. S., et al.	Sprangers, M. A., et al. (EORTC Quality of Life Group)
Jenis	Self-report questionnaire	Self-report questionnaire
Sumber perintis	Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., & Brook, R. H. (1998). The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 36(7), 1002–1012.	Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., et al. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol, 14(10), 2756–2768.
Alias	UCLA PCI, PCI	QLQ-BR23
Berkaitan	5	5
Ringkasan	The UCLA Prostate Cancer Index (UCLA PCI) is a 20-item, prostate-cancer-specific quality-of-life instrument focused on functional outcomes (urinary, sexual, bowel) rather than general cancer QoL. Developed by Litwin et al. in 1998, it has become the standard functional assessment tool in prostate cancer outcomes research, particularly for treatment comparison studies evaluating surgical vs. radiation outcomes.	The EORTC QLQ-BR23 is a 23-item breast-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire, assessing functional and symptom domains unique to breast cancer. Validated by Sprangers et al. in 1996, it measures body image, sexual function, breast symptoms, and arm symptoms, making it a standard instrument in European and international breast cancer clinical trials and quality-of-life research.